• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Citius Pharmaceuticals, Inc. Announces Appointment of Ilanit Allen as Vice President, Corporate Communications and Investor Relations

    5/17/21 12:30:00 PM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTXR alert in real time by email

    CRANFORD, N.J., May 17, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR) today announced that Ilanit Allen has been appointed Vice President of Corporate Communications and Investor Relations, effective immediately.  In this newly created role, Ms. Allen will spearhead financial communication and investor activities, reporting to Myron Holubiak, President and Chief Executive Officer of Citius.

    "We are thrilled to welcome Ilanit to the Citius team as we advance our pipeline of first-in-class critical care products," stated Mr. Holubiak. "I am confident that Ilanit's extensive communications and investor relations experience, coupled with her financial and strategic mindset, will be an invaluable resource for our investors and the broader financial community. With multiple expected milestones on the horizon, we look forward to leveraging Ilanit's expertise in communicating the Citius story with our stakeholders."

    "The Citius leadership team has a distinguished track record of successfully bringing important pharmaceutical products to market. I look forward to engaging with the investment community to share the Company's growth strategy and value-drivers, as management continues to position Citius to deliver long-term growth for shareholders," stated Ms. Allen.

    Ms. Allen joins Citius with more than 20 years of experience in corporate communications, investor relations, strategy and investment banking. Since 2014, Ms. Allen has provided investor relations counsel to more than two dozen private and public life science companies. Previously, she advised executives across a broad spectrum of industries and growth stages, including technology startups and Fortune 500 financial institutions. Ilanit began her career as an investment banking analyst at SG Cowen with a focus on mergers and acquisitions. Ms. Allen holds an MBA from Harvard Business School, a Bachelor of Science degree in Finance from The Wharton School, and a Bachelor of Arts degree in International Relations from the University of Pennsylvania.

    Andrew Scott, Vice President of Special Projects, will assume greater responsibility for business development activities and will remain a resource for the investment community.

    About Citius Pharmaceuticals, Inc.

    Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. The Company's lead product candidate, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), is currently enrolling patients in a Phase 3 pivotal superiority trial.  Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19.  For more information, please visit www.citiuspharma.com.

    Safe Harbor

    This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.  Factors that could cause actual results to differ materially from those currently anticipated are: our ability to attract, integrate, and retain key personnel; our ability to successfully undertake and complete clinical trials and the results from those trials for our product candidates; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our need for substantial additional funds; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; government regulation; competition; as well as other risks described in our SEC filings. These risks have been and may be further impacted by Covid-19. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission ("SEC") filings which are available on the SEC's website at www.sec.gov, including in our Annual Report on Form 10-K for the year ended September 30, 2020, filed with the SEC on December 16, 2020 and updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

    Investor Relations for Citius Pharmaceuticals:

    Andrew Scott

    Vice President, Special Projects

    T: 908-967-6677 x105

    E: [email protected]

    Ilanit Allen

    Vice President, Corporate Communications and Investor Relations

    T: 908-967-6677 x113

    E: [email protected]

     

    Cision View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-announces-appointment-of-ilanit-allen-as-vice-president-corporate-communications-and-investor-relations-301292639.html

    SOURCE Citius Pharmaceuticals, Inc.

    Get the next $CTXR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CTXR

    DatePrice TargetRatingAnalyst
    12/30/2024$9.00Hold → Buy
    D. Boral Capital
    1/18/2022$4.00 → $6.00Buy
    HC Wainwright & Co.
    11/30/2021$4.00Buy
    Maxim Group
    More analyst ratings

    $CTXR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citius Pharmaceuticals upgraded by D. Boral Capital with a new price target

      D. Boral Capital upgraded Citius Pharmaceuticals from Hold to Buy and set a new price target of $9.00

      12/30/24 7:26:29 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Citius Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Citius Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $4.00 previously

      1/18/22 10:01:19 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Citius Pharmaceuticals with a new price target

      Maxim Group initiated coverage of Citius Pharmaceuticals with a rating of Buy and set a new price target of $4.00

      11/30/21 8:45:24 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTXR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

      CRANFORD, N.J., June 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced that preparations for the commercial launch of LYMPHIR™, an FDA-approved immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), are nearing completion. The Company believes it is now operationally positioned to transition from a development-stage enterprise to a fully integrated commercial organization, with all major launch-enabling activities underway. Final preparations are in process for a U.S. launch of LYMPHIR in the second h

      6/17/25 8:08:00 AM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • After Major Oncology Conference, All Eyes Turn to Industry Innovation

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

      6/12/25 9:00:00 AM ET
      $CAH
      $CTOR
      $CTXR
      $ONCY
      Other Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

      $6 million upfront with up to an additional $9.8 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants CRANFORD, N.J., June 12, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase of an aggregate of 4,920,000 shares of its common stock  (or pre-funded warrants in lieu thereof) and accompanying short-term warrants to purchase up to an aggregate of 9,

      6/12/25 8:35:00 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTXR
    Leadership Updates

    Live Leadership Updates

    See more
    • After Major Oncology Conference, All Eyes Turn to Industry Innovation

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

      6/12/25 9:00:00 AM ET
      $CAH
      $CTOR
      $CTXR
      $ONCY
      Other Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls

      CRANFORD, N.J., Nov. 5, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced the appointment of pharmaceutical industry veteran Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls (CMC). Mr. Creighton will be responsible for the global strategic regulatory and manufacturing development plans for Citius's five pipeline programs. "With two late P

      11/5/21 9:15:00 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals, Inc. Announces Appointment of Ilanit Allen as Vice President, Corporate Communications and Investor Relations

      CRANFORD, N.J., May 17, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR) today announced that Ilanit Allen has been appointed Vice President of Corporate Communications and Investor Relations, effective immediately.  In this newly created role, Ms. Allen will spearhead financial communication and investor activities, reporting to Myron Holubiak, President and Chief Executive Officer of Citius. "We are thrilled to welcome Ilanit to the Citius team as we advance our pipeline of first-in-class critical care products," stated Mr. Holubiak. "I am confident that Ilanit's extensive communications and investor relations experience, coupled with her financia

      5/17/21 12:30:00 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTXR
    Financials

    Live finance-specific insights

    See more
    • Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

      Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL);Advanced ma

      12/27/24 5:00:00 PM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

      Management call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), today announced that it will host an investor call on Tuesday, August 13, 2024 at 8:30 am ET to discuss recent and upcoming developments. Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team. A question and answer period will follow management's discussion. Conference Call Details: Date: Tuesday, August 13, 2024 Time: 8:30 a.m. Eastern Time Dial In: 1-888-243-4451 (U.S. toll free) 1-412-542-4135 (international) Webcast: Register for the webcast here. A replay will

      8/12/24 8:00:00 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

      Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET CRANFORD, N.J., May 29, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it will host an investor call on Monday, June 3, 2024 at 8:30 am ET to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution. Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team to discuss the results of the Phase 3 Trial and the clinical need for Mino-Lok in patients with catheter-related blood

      5/29/24 8:30:00 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTXR
    SEC Filings

    See more
    • Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

      6/12/25 8:45:29 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Citius Pharmaceuticals Inc.

      424B5 - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

      6/11/25 8:00:15 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

      6/9/25 5:29:24 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTXR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Webb Carol

      4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

      11/12/24 5:00:31 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Dutia Suren G

      4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

      11/12/24 5:00:22 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Vice Chairman Holubiak Myron Z

      4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

      11/12/24 5:00:18 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTXR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Citius Pharmaceuticals Inc.

      SC 13D/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

      11/27/24 4:05:31 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Citius Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

      5/8/24 2:22:56 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Citius Pharmaceuticals Inc.

      SC 13G - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

      1/31/24 2:08:26 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care